Sikander Ailawadhi

Sikander Ailawadhi, M.D. is a Professor of Medicine at Mayo Clinic in Jacksonville, Florida, with primary appointments as Consultant in the Division of Hematology/Oncology, Department of Internal Medicine, and as a Consultant in the Department of Cancer Biology.

Dr. Ailawadhi's career focuses on the treatment of plasma cell disorders, particularly multiple myeloma and Waldenstrom macroglobulinemia. His research spans four key areas: drug development in multiple myeloma, cellular therapy in plasma cell disorders, healthcare disparities research, and pragmatic real-world clinical trials. He has led numerous clinical trials from phase 1 to phase 3, including groundbreaking CAR-T cell therapy trials that contributed to FDA approvals.

His publication record shows significant growth over time, with 221 research outputs to date. Recent publications (2025) demonstrate his continued leadership in multiple myeloma research, focusing on treatment patterns, therapeutic optimization, emerging approaches, and special populations like frail older adults.

• 2024 Research Impact Award from HealthTree Foundation
• 2024 Top Clinical Trial Accruing Provider of the Year at Mayo Clinic Florida
• 2015 Ambassador Newcomer Award from Mayo Clinic
• 2013 Cancer Clinical Investigator Team Leadership Award from NIH/NCI

Dr. Ailawadhi holds leadership positions including Diversity, Equity and Inclusion Lead for the Multiple Myeloma SPORE at Mayo Clinic Comprehensive Cancer Center (2023-present), Enterprise Deputy Director of the International Cancer Program at Mayo Clinic (2023-present), and Member of the Myeloma Steering Committee at the National Cancer Institute (2023-present). His work addresses critical healthcare disparities in cancer treatment and clinical trial participation, with a special focus on making trials more representative of real-world populations.